Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Speaks Out Against Build Back Better Bill

US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers

Executive Summary

The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.

You may also be interested in...



AAM Blasts Build Back Better But Bernstein Offers Balance

Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.

Strange Bedfellows: Generics Firms Join Big Pharma In Opposing US Price Negotiation Legislation

Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the US generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.

Medicare Price Inflation Rebates In Build Back Better Bill Are Prospective Only

The legislation would also establish new manufacturer discounts in Medicare Part D as part of a redesign of the benefit that includes a cap on beneficiary out-of-pocket spending. Negotiations are still fluid on the overall legislative package, however, and things could change.

Related Content

Topics

UsernamePublicRestriction

Register

GB151433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel